Key result
ACDA-heparin anticoagulation improves sensitivity in ASTM thrombogenicity testing versus biomaterials.
Why the study?
The ASTM F2888-19 standard for assessing platelet and leukocyte interactions with blood-contacting device materials has low test sensitivity for leukocyte count and requires a high test sample surface area to blood ratio of 12 cm2/mL.
Does anticoagulating donor blood with ACDA (recalcified and heparinized to 1 U/mL) at a reduced exposure ratio of 6 cm2/mL improve the sensitivity of the ASTM F2888-19 assay for differentiating material thrombogenicity via platelet and leukocyte counts compared to the standard 3.2% sodium citrate protocol?
Does anticoagulating donor blood with ACDA (recalcified and heparinized to 1 U/mL) at a reduced exposure ratio of 6 cm2/mL improve the sensitivity of the ASTM F2888-19 assay for differentiating material thrombogenicity via platelet and leukocyte counts compared to the standard 3.2% sodium citrate protocol?
Answers are grounded in this paper and cite their sources.
Using ACDA-anticoagulated blood with 1 U/mL heparin and physiological recalcification significantly improves the sensitivity of the ASTM F2888-19 in vitro thrombogenicity assay to differentiate blood-contacting device materials based on both leukocyte and platelet counts while halving the required sample surface area to 6 cm2/mL.
The ASTM F2888‐19 standard for platelet and leukocyte count assay is the only standardized test method for assessing platelet and leukocyte interactions with blood‐contacting device materials. This study aimed to address two limitations of the ASTM F2888‐19 standard: low test sensitivity for leukocyte count and high test sample surface area to blood ratio (12 cm 2 /mL). Human blood from healthy adult donors was drawn into polypropylene tubes with either 3.2% sodium (Na) citrate or anticoagulant citrate dextrose solution A (ACDA). Immediately before starting the test, the blood was recalcified and heparinized to a concentration of 1, 1.5, or 2 U/mL and incubated with the test materials of varying thrombogenic potential at an exposure ratio of 6 or 12 cm 2 /mL for 1 h at 37°C ± 2°C in a shaking water bath. Complete blood count was measured using a hematology analyzer. The results show that both, Na‐citrated blood (6 or 12 cm 2 /mL exposure ratio) and ACDA blood (6 cm 2 /mL ratio), were able to differentiate thrombogenic materials from commonly used biomaterials based on platelet count changes. The magnitudes of difference between the thrombogenic materials and biomaterials depends on heparin concentration. The test sensitivity was highest when ACDA blood, heparinized to 1 U/mL heparin, was used. Moreover, the use of ACDA blood, unlike Na‐citrated blood, also allowed the assay to distinguish between the thrombogenic materials from commonly used biomaterials based on leukocyte count changes. In conclusion, the use of ACDA blood significantly increased test sensitivity of the ASTM F2888‐19 test method in differentiating materials with varying thrombogenicity based on both platelet and leukocyte counts, while reducing blood exposure ratio to 6 cm 2 /mL. These findings will be used to revise the ASTM F2888 standard in the future.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2024) studied In vitro thrombogenicity assessment of blood-contacting medical device materials (healthy adult blood donors) (n=7). Anticoagulant citrate dextrose solution A (ACDA) anticoagulated blood vs. 3.2% sodium (Na) citrate anticoagulated blood (90:10 blood to Na-citrate ratio), recalcified with 10 mM CaCl2 and heparinized to 1.0, 1.5, or 2.0 U/mL heparin at 6 or 12 cm2/mL material surface area to blood volume ratio was evaluated on Normalized platelet and leukocyte counts (% of negative control) after 1-hour incubation with thrombogenic positive control materials (Buna-N rubber, latex, glass beads) versus biomaterials (PTFE, HDPE, silicone, 316L stainless steel) (p=<0.05). ACDA-anticoagulated blood with 1 U/mL heparin at 6 cm2/mL reduced positive-control platelet and leukocyte counts vs biomaterials, improving ASTM F2888-19 sensitivity.
Synapse has enriched 10 related papers. Consider them for comparative context: